Global Chlamydia Infection Diagnostics and Therapeutics Industry

Global Chlamydia Infection Diagnostics and Therapeutics Industry

  • April 2021 •
  • 284 pages •
  • Report ID: 5960844 •
  • Format: PDF
Abstract:
- Global Chlamydia Infection Diagnostics and Therapeutics Market to Reach $1.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Chlamydia Infection Diagnostics and Therapeutics estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at aCAGR of 4.9% over the period 2020-2027. Diagnostics, one of the segments analyzed in the report, is projected to record 5.1% CAGR and reach US$1.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Therapeutics segment is readjusted to a revised 4.4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $373.7 Million, While China is Forecast to Grow at 7.5% CAGR
- The Chlamydia Infection Diagnostics and Therapeutics market in the U.S. is estimated at US$373.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$394.4 Million by the year 2027 trailing a CAGR of 7.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

- Select Competitors (Total 44 Featured) -
  • Abbott Laboratories, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad laboratories Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Siemens AG
  • Thermo Fisher Scientific, Inc.